Hypofractionated radiotherapy with a tumor bed boost for early breast cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the use of hypofractionated radiotherapy combined with a concomitant tumor bed boost for patients with early-stage breast cancer or ductal carcinoma in situ following partial mastectomy. The approach aims to improve local control of the disease while minimizing treatment duration. Female patients aged 20 and older with a Karnofsky Performance Status of 70% or higher are eligible for participation. The study is observational and focuses on assessing the effectiveness of this treatment regimen.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Female patients with histologically confirmed early-stage breast cancer (T1-2 and N0-1) or ductal carcinoma in situ (DCIS).
* Patients undergoing breast-conserving surgery
* Age ≥ 20 years
* Karnofsky Performance Status (KPS) ≥70%
* Life expectancy ≥ 5 years
* Adequate renal and hepatic function

Exclusion Criteria:

* Pregnant patients
* Patients requiring re-irradiation of the thoracic region

Where it's running

• National Taiwan University Hospital Yunlin Branch
  Taipei, Taiwan Recruiting
• National Taiwan University Hospital
  Taipei, Taiwan, Taiwan Not yet recruiting

Study contacts

• Study coordinator: Yen-Ting Liu
• Email: nickliucool@ntuh.gov.tw
• Phone: 88697255451

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Giredestrant in ER-positive, HER2-negative early breast cancer: who tolerates it and sticks with treatment

  This study tests how well people with ER-positive, HER2-negative early breast cancer can tolerate and stay on giredestrant, and how they feel during treatment.

  Recruiting Phase 3 Hoffmann-La Roche · Québec, Quebec · NCT07827573

• Skipping sentinel lymph node biopsy for older women with luminal A early breast cancer

  This trial tests whether women over 59 with early luminal A, node‑negative breast cancer can safely skip sentinel lymph node biopsy and have breast surgery guided by imaging instead.

  Recruiting N.N. Petrov National Medical Research Center of Oncology · Saint Petersburg, Russian Federation · NCT07579286

• Giredestrant after aromatase inhibitor intolerance in early ER+/HER2- breast cancer

  This study tests switching to giredestrant for postmenopausal women with ER+/HER2- early breast cancer who had AI intolerance, to see if it’s tolerable and can improve patient-reported outcomes.

  Recruiting at 8 sites Phase 3 Genentech, Inc. · Fountain Valley, California and 7 other locations · NCT07541079

• Adherence to Cell Cycle Inhibitors with Endocrine Therapy in Localized High-Risk ER+ Breast Cancer

  This study checks how well patients with localized ER+ breast cancer stick to a combined endocrine therapy and CDK4/6 inhibitor after surgery.

  Recruiting University Hospital, Grenoble · Grenoble · NCT07443774

• Managing chemotherapy side effects with a smartphone symptom app plus telenursing

  This trial tests whether a smartphone symptom-reporting app combined with a standardized telenursing program helps adults starting first-cycle chemotherapy for gastric, lung, breast, or colon cancer manage treatment side effects.

  Recruiting at 4 sites Ulsan University Hospital · Busan and 4 other locations · NCT07405931

• MRI-guided early surgery and reduced chemotherapy for stage II–III triple-negative breast cancer

  This trial will try using MRI to decide whether adults with stage II–III triple-negative breast cancer who are receiving a pembrolizumab-containing neoadjuvant regimen can have earlier surgery and less chemotherapy.

  Recruiting at 2 sites Phase 2 Tel-Aviv Sourasky Medical Center · Tel Aviv and 1 other locations · NCT07327021

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.